Trial Profile
WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2022
Price :
$35
*
At a glance
- Drugs Leukaemia DNA vaccine (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia
- Focus Biomarker; Therapeutic Use
- Acronyms WIN
- 05 Sep 2018 Status changed from suspended to completed.
- 29 Jun 2013 Status changed from recruiting to suspended as reported by European Clinical Trials Database.
- 10 Jan 2013 Accrual to date is 12% according to United Kingdom Clinical Research Network.